You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of an Orally Available Therapeutic for Neutralizing C. difficile Toxin B
SBC: NECTAGEN INC Topic: NIAIDInfection with the bacterium C. difficile is the most common and increasingly prevalent cause of diarrhea. In the United States, cases of C. difficile infection (CDI) are estimated to number 500,000 annually and to result in an estimated 15,000 to 30,000 deaths. The cost of these cases is thought to exceed $4.8 billion annually. CDI continues to cause discomfort, serious illness and sometimes deat ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Targeting Myosin to Treat Polycystic Kidney Disease
SBC: PLUREXA LLC Topic: 400PROJECT SUMMARY The goal of this proposal is to advance a new therapeutic approach targeting myosin for polycystic kidney disease (PKD). PKD is a major life-threatening Mendelian disorder that affects 12,000,000 individuals, representing a market opportunity of ~$1 billion. In PKD, tiny tubules in the kidneys, liver, and other organs gradually expand into fluid-filled cysts, leading to organ failu ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Dialysate regeneration system based on photo-electrochemical urea oxidation and reactive adsorption to enable portable hemodialysis
SBC: KULEANA TECHNOLOGY, INC. Topic: 400PROJECT SUMMARY/ ABSTRACT Currently in the US there are over 400,000 kidney patients on dialysis. The primary therapy mode is hemodialysis and is performed in a hospital or private clinic. Current dialysis therapy requires a large device that must be continuously connected to a reverse osmosis (RO) system. A single treatment will require over 150L of AAMI dialysate making portable device unattaina ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel diagnostic biomarker reference standards for newborn screening of Mucopolysaccharidoses type I and II.
SBC: GELBCHEM, LLC Topic: NICHDProject Summary The goal of this project is to design and prepare diagnostic biomarker reference standards for the endogenous glycosaminoglycan (GAG) Mucopolysaccharidosis type I (MPS-I) and type II (MPS- II) biomarkers. MPS-I and MPS-II are lysosomal storage disorders (LSDs) which are listed on the Recommended Uniform Screening Panel (RUSP) in the United States and are included in global Newborn ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Real-time Multimodal Diffuse Reflectance and Polarization Imaging Based Nerve Identification in Surgical Field of View
SBC: YAYA SCIENTIFIC LLC Topic: NIBIBPROJECT SUMMARY We propose to develop a novel non-contact, label-free multimodality imager that provides real-time intraoperative identification of nerves within the surgical field-of-view to facilitate the prevention of unintended nerve damage (termed iatrogenic nerve injury) during surgical procedures, as they are a major source of postsurgical complications, e.g., chronic pain. In the United St ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Multispectral Sensor for Chemical Composition Analysis of Ultrafine Aerosols in Air Quality Assessment
SBC: SPECTREE INC. Topic: RProject SummaryWe propose developing and validating a novel platform technology that combines the collection and chemical analysis of ultrafine particles using an in-situ multispectral technique. The sample, collected directly onto the analysis substrate, is analyzed via excitation-emission matrix (EEM) spectroscopy. This approach will be validated against laboratory combustion-generated aerosols, ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
STARTUP Central
SBC: CONTINUUM EDUCATIONAL TECHNOLOGIES, PBC Topic: 500PROJECT SUMMARY Continuum Educational Technologies’ (Continuum) will work with the University of Kansas (KU) on the proposed I-RED program entitled Smart Tools to Accelerate Research Translation by Uplifting Participants for the Central IDeA State Region (STARTUP Central) program to stimulate technological innovation in the IDeA state regions by addressing the entrepreneurial educational needs o ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimizing Small Molecule Mechanomimetics to Treat Age-related Osteoporosis.
SBC: OAK RIDGE THERAPEUTIC DISCOVERY LLC Topic: NIAAbstract There is an unmet need to develop treatments for senile osteoporosis, a disorder characterized by an age-related reciprocal decrease in osteogenesis and increase in bone marrow fat. Senile osteoporosis resembles disuse osteopenia, suggesting its pathogenesis involves impaired bone mechanosensing. We discovered that the polycystin heterotrimeric complex (1PC1+3PC2) functions as a mechanose ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing a selective TRPC3 ion channel inhibitor for epilepsy treatment
SBC: SEAK Therapeutics, LLC Topic: 106Project SummaryEpilepsy is one of the most common brain disorders. Current drugs have limited efficacy. Identifying new targeted drugs that can be used as safer, more effective therapies is in urgent unmet need. Selective inhibition of the transient receptor potential canonical 3 (TRPC3) emerges as a novel strategy to impede epilepsy. However, the currently best selective TRPC3 inhibitor, Pyr3, ha ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Cell permeant peptidomimetics to prevent delayed vasospasm and neurological deficits after subarachnoid hemorrhage
SBC: VasaMetrix Topic: 107PROJECT SUMMARYSubarachnoid hemorrhage (SAH) due to rupture of an intracranial aneurysm leads to delayed vasospasm resulting in neuroischemia (stroke). The overall morbidity (profound neurologic deficit in 10-20% of survivors) and mortality (50%) are high, and the disease affects a relatively young adult population. Therapeutic options to prevent delayed vasospasm and neuroischemia after SAH are c ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health